{"id":"https://genegraph.clinicalgenome.org/r/5318656f-c898-46b0-861d-5dfcb6605ae2v1.0","type":"EvidenceStrengthAssertion","dc:description":"\t\nBiallelic MALT1 germline loss of function variants were first identified in two siblings with combined immunodeficiency (CID) in 2013 (PMID: 23727036). Autosomal recessive MALT1 deficiency is associated with a combination of recurrent bacterial, viral, or fungal infections, periodontal disease, enteropathy, dermatitis, and failure to thrive. Immunological defects are variable, but typically include normal total T lymphocyte numbers, impaired B cell development with normal/decreased numbers, and variable eosinophilia. There is impaired T cell mitogen proliferation and reduction in Foxp3+ regulatory CD4 T (Treg) cells as well as T helper 17 (TH17) cells. 11 variants have been reported and are composed of missense, frameshift, splice site and indel variants resulting in the loss of function of MALT1. Evidence supporting this gene-disease relationship includes case-level and experimental data. 7 unique variants from 7 individuals across 6 publications were curated  (PMID: 23727036, 27253662, 24332264, 31037583, 32858082, 25627829). Heterozygous carriers have not been shown to have a clinical phenotype. More evidence is available in the literature, but the maximum score for genetic evidence has been reached (12 pts).\n\nExperimentally, in vitro studies studying MALT1 function use patient derived cells to support this gene-disease relationship. MALT1 is a paracaspase that regulates antigen receptor signaling pathways in lymphocytes. In response to antigen receptor signaling, -MALT1 serves as a scaffold protein for BCL10 and associates with CARD family proteins to generate the CBM signalosome complex. This CBM complex recruits signaling intermediates that lead to the activation of the NF-kB, c-Jun N-terminal kinase (JNK) and the mechanistic target of rapamycin (mTOR) pathways. The MALT1 protein has been shown to be expressed in T and B lymphocytes and is absent in patients with biallelic MALT1 variants with associated CID (PMID:30692685). In vitro functional data demonstrates altered NF-kB signaling in patient cells with MALT1 variants, with associated changes in downstream activation, proliferation, and cytokine production in lymphocytes (PMID:30692685). Mouse models of MALT1 deficiency or alterations of the protease domain show defects in generation and maintenance of B and T lymphocytes, alterations in Foxp3+ regulatory T cell development and alterations in serum immunoglobulin levels (PMID:14576442, 26405015, 25762782). These phenotypic changes are associated with alteration in NF-kB signaling, replicating those defects seen in patients. In summary, MALT1 is definitively associated with combined immunodeficiency. This association has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time.\nÂ \nThis classification was approved by the ClinGen SCID-CID Working Group on 7/21/2022  (SOP Version 9).\n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/5318656f-c898-46b0-861d-5dfcb6605ae2","GCISnapshot":"https://genegraph.clinicalgenome.org/r/537efc87-5f45-489b-9aa0-6bd3e029754e","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/537efc87-5f45-489b-9aa0-6bd3e029754e_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10081","date":"2022-12-16T17:26:19.857Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/537efc87-5f45-489b-9aa0-6bd3e029754e_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10081","date":"2022-07-21T16:00:00.000Z","role":"Approver"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/537efc87-5f45-489b-9aa0-6bd3e029754e_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/537efc87-5f45-489b-9aa0-6bd3e029754e_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/14297f0a-184a-4428-8251-406568585c20","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4fa7b3f2-3da4-42f5-8d1b-f34e449dcbc2","type":"Finding","dc:description":"Mice with MALT1 deficiency show a defect in Foxp3+ regulatory T cell generation and maintenance. Patients with MALT1 deficency show a reduction in Treg cell frequency compared to control patients. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26405015","rdfs:label":"Treg defect","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/a816370f-5141-4359-a119-cf35339d52ef","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/31a21207-dfce-4289-a61a-ad73e31c1000","type":"Finding","dc:description":"In humans, many patients have low antibody levels and require IVIG, and mice have a defect in serum antibody levels. CD3 induced proliferation is reduced in both patients and these KO mice.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14576442","rdfs:label":"MALT1 KO mouse","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/537efc87-5f45-489b-9aa0-6bd3e029754e_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bc016f1a-dd42-4a98-8115-bea581efb98a","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5379b453-15c1-47cf-bf4c-4703ce08e62a","type":"FunctionalAlteration","dc:description":"Reduced p-p65 following PMA/Ionomycin stimulation.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30692685","rdfs:label":"Human cells NFKB function"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/537efc87-5f45-489b-9aa0-6bd3e029754e_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8c2ac432-4f6c-4295-865c-db3c83ac1834","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6f9ae540-5e92-49f0-95e7-18e1efded09e","type":"Finding","dc:description":"Stimulation of patient cells with MALT1 variant using anti-CD3 show a defect in NFKB activation, similar to what is seen in the mouse cells.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25762782","rdfs:label":"Mouse MALT1 function","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/628bc4f7-9790-45ea-b2fa-1e8bcb044526","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5e0517aa-6596-435d-85d8-1dc510b4f123","type":"Finding","dc:description":"Reduced expression in patients with homozygous MALT1 variants","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30692685","rdfs:label":"MALT1 expression in patients","demonstrates":{"id":"cg:GeneExpressionB"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6},{"id":"https://genegraph.clinicalgenome.org/r/537efc87-5f45-489b-9aa0-6bd3e029754e_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/93fe47df-88fc-45e0-8007-860e86cde950_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/96b17197-7600-404b-b205-db4d23f92bc2","type":"EvidenceLine","dc:description":"shown loss of MALT1 expression, with functional data","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/96b17197-7600-404b-b205-db4d23f92bc2_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Reduced IL-2 production following PMA/Ionomycin, reduced MALT1 expression by western of PBMCs, reduced mTOR and NFKB signaling in patient cells","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/96b17197-7600-404b-b205-db4d23f92bc2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31037583","allele":{"id":"https://genegraph.clinicalgenome.org/r/3dfe519b-8e5d-49dc-8db0-e221e745ff13","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006785.4(MALT1):c.1799T>A (p.Ile600Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA402575813"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/93fe47df-88fc-45e0-8007-860e86cde950","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31037583","rdfs:label":"P2","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":5,"allele":{"id":"https://genegraph.clinicalgenome.org/r/3dfe519b-8e5d-49dc-8db0-e221e745ff13"},"detectionMethod":"WES followed by Sanger","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001045","obo:HP_0031382","obo:HP_0004313","obo:HP_0001806","obo:HP_0001525","obo:HP_0001051"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/96b17197-7600-404b-b205-db4d23f92bc2_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/0b5ee980-a591-4b7a-8ab3-b333eac9d5ae_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b9b4ac34-6b5c-47c9-9454-26525b2dcd6e","type":"EvidenceLine","dc:description":"Showed no protein expression due to this homozygous variant, strong functional data.","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b9b4ac34-6b5c-47c9-9454-26525b2dcd6e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"mRNA levels are comparable to normal and heterozygotes, but patients with the homozygous mutation show no protein expression. Patient PBMCs showed no IL-2 production or IkBa after stimulation with PMA/Ionomycin. Patient variant did not reconstitute MALT1 function in MALT deficient mice.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/b9b4ac34-6b5c-47c9-9454-26525b2dcd6e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23727036","allele":{"id":"https://genegraph.clinicalgenome.org/r/efedfcc6-1bdb-4d05-960d-2d2ef109aadd","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006785.4(MALT1):c.266G>T (p.Ser89Ile)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA144882"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/0b5ee980-a591-4b7a-8ab3-b333eac9d5ae","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23727036","rdfs:label":"IV.1","ageType":"AgeAtDeath","ageUnit":"Years","ageValue":14,"allele":{"id":"https://genegraph.clinicalgenome.org/r/efedfcc6-1bdb-4d05-960d-2d2ef109aadd"},"detectionMethod":"Chromosomal microarray on family, followed by whole genome, followed by Sanger sequencing","firstTestingMethod":"Chromosomal microarray","phenotypes":["obo:HP_0000230","obo:HP_0006946","obo:HP_0002878","obo:HP_0100633","obo:HP_0001510","obo:HP_0005263","obo:HP_0006538","obo:HP_0100825","obo:HP_0031379","obo:HP_0011107","obo:HP_0000265","obo:HP_0002110"],"previousTesting":false,"secondTestingMethod":"Whole genome shotgun sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/b9b4ac34-6b5c-47c9-9454-26525b2dcd6e_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/3f825d1e-f213-4d47-9c42-478558486001_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/053cd142-cf32-4c62-aa03-faa6bfdb8a42","type":"EvidenceLine","dc:description":"Functional data only shows partial reduction in NKFB signaling, while expression data shows no defect and general NFKB expression following PMA/Iono or CD3/CD28 did not show any changes in variant cells.","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/053cd142-cf32-4c62-aa03-faa6bfdb8a42_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Transfection into MALT1 deficient Jurkat shows reduction of NFKB signaling compared to WT MALT1 sequence. However, there is only a partially reduced phenotype and doesn't fully explain the genotype/phenotype association.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/053cd142-cf32-4c62-aa03-faa6bfdb8a42_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32858082","allele":{"id":"https://genegraph.clinicalgenome.org/r/dd16b107-1d47-40ca-9e95-09dafc75a64b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006785.4(MALT1):c.2418G>C (p.Glu806Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA402577599"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/3f825d1e-f213-4d47-9c42-478558486001","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32858082","rdfs:label":"P1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":19,"allele":{"id":"https://genegraph.clinicalgenome.org/r/dd16b107-1d47-40ca-9e95-09dafc75a64b"},"firstTestingMethod":"Next generation sequencing panels","phenotypes":["obo:HP_0003765","obo:HP_0006538","obo:HP_0001051","obo:HP_0000126","obo:HP_0100750","obo:HP_0000365","obo:HP_0002716","obo:HP_0200043","obo:HP_0410240","obo:HP_0002110","obo:HP_0000403"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/053cd142-cf32-4c62-aa03-faa6bfdb8a42_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/f6aa501f-2fd9-4158-9639-79cdef691cd3_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c978257d-8d9e-4387-949c-b97e8cae34c6","type":"EvidenceLine","dc:description":"This variant was already scored in sibling.","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c978257d-8d9e-4387-949c-b97e8cae34c6_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"No protein expression, no IL-2/Ikba up regulation after PMA/IO, no reconstitution of MALT1 function in MALT1 ko mouse","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/c978257d-8d9e-4387-949c-b97e8cae34c6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23727036","allele":{"id":"https://genegraph.clinicalgenome.org/r/efedfcc6-1bdb-4d05-960d-2d2ef109aadd"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/f6aa501f-2fd9-4158-9639-79cdef691cd3","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23727036","rdfs:label":"IV.2","ageType":"AgeAtDeath","ageUnit":"Years","ageValue":7,"allele":{"id":"https://genegraph.clinicalgenome.org/r/efedfcc6-1bdb-4d05-960d-2d2ef109aadd"},"detectionMethod":"chromosomal microarray, followed by WGS, followed by Sanger sequencing","firstTestingMethod":"Chromosomal microarray","phenotypes":["obo:HP_0100633","obo:HP_0006946","obo:HP_0002110","obo:HP_0000230","obo:HP_0000265","obo:HP_0006538","obo:HP_0031379","obo:HP_0011107","obo:HP_0005263","obo:HP_0100825","obo:HP_0001510","obo:HP_0002878"],"secondTestingMethod":"Whole genome shotgun sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/c978257d-8d9e-4387-949c-b97e8cae34c6_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/dc2f5dfb-43e6-4e34-9573-8255cdc5ba23_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e77d1a6b-f1cb-440e-87f3-911fc7332436","type":"EvidenceLine","dc:description":"null for protein and strong functional evidence.","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e77d1a6b-f1cb-440e-87f3-911fc7332436_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Protein and Ikba uprgulation after stimulation was absent from patient cells. Patient underwent HSC, and Ikba protein expression was recovered and some symptoms improved.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/e77d1a6b-f1cb-440e-87f3-911fc7332436_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27253662","allele":{"id":"https://genegraph.clinicalgenome.org/r/e3a1e1ec-8894-4970-8716-a8433e5c2165","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006785.4(MALT1):c.550G>T (p.Asp184Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA402572814"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/dc2f5dfb-43e6-4e34-9573-8255cdc5ba23","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27253662","rdfs:label":"P1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":7,"allele":{"id":"https://genegraph.clinicalgenome.org/r/e3a1e1ec-8894-4970-8716-a8433e5c2165"},"detectionMethod":"Exome followed by Sanger sequencing","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0002028","obo:HP_0002841","obo:HP_0001999","obo:HP_0004429","obo:HP_0000964","obo:HP_0011473","obo:HP_0031382","obo:HP_0002718"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/e77d1a6b-f1cb-440e-87f3-911fc7332436_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/44eeb53f-1bad-46d6-bbae-1b18ff508dcc_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/894114de-cacf-4692-8d62-e0f2006f89a9","type":"EvidenceLine","dc:description":"Do not show that individual variant drives phenotype seen","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/894114de-cacf-4692-8d62-e0f2006f89a9_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"shows loss of MALT1 protein by western blot, PCR showed loss of exon 10 and shorted transcripts. Host cells showed reduction in pNFKB, IkB, IL2 function. Transfection of WT MALT1 reversed defect.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/894114de-cacf-4692-8d62-e0f2006f89a9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25627829","allele":{"id":"https://genegraph.clinicalgenome.org/r/99cbad1e-b899-4c19-aba6-1b737a08e51c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006785.3:c.1019-2A>G","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA051273"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/30ccd80a-b77c-42de-96a7-965ebf5e1946","type":"EvidenceLine","dc:description":"Does not show that individual variants drive phenotype seen","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/30ccd80a-b77c-42de-96a7-965ebf5e1946_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"showed absence of cDNA, suggesting nonsense mediated decay. Mother showed reduction in MALT1 protein. Host cells showed reduction in pNFKB, IkB, IL2 function. Transfection of WT MALT1 reversed defect.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/30ccd80a-b77c-42de-96a7-965ebf5e1946_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25627829","allele":{"id":"https://genegraph.clinicalgenome.org/r/93347825-1a0c-492c-9144-b513bdead30f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006785.3(MALT1):c.[1019-2A>G];[1060delC]","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA051281"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/44eeb53f-1bad-46d6-bbae-1b18ff508dcc","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25627829","rdfs:label":"P1","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":1,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/93347825-1a0c-492c-9144-b513bdead30f"},{"id":"https://genegraph.clinicalgenome.org/r/99cbad1e-b899-4c19-aba6-1b737a08e51c"}],"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0025085","obo:HP_0040189","obo:HP_0004313","obo:HP_0032247","obo:HP_0000388","obo:HP_0032167","obo:HP_0001510","obo:HP_0011950","obo:HP_0009098"],"sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/894114de-cacf-4692-8d62-e0f2006f89a9_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/30ccd80a-b77c-42de-96a7-965ebf5e1946_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/1d2e674d-f725-4bb8-a22b-b62df9c74b67_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/354dd027-34d9-444d-99d5-830d3f826062","type":"EvidenceLine","dc:description":"Functional data was weak, did not show protein expression, did not read out true proliferation, or cytokine production defect.","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/354dd027-34d9-444d-99d5-830d3f826062_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"MALT1 variant was unable to bind to BCL10 complex, was unable to proliferate (as read out by cell size) following PHA","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/354dd027-34d9-444d-99d5-830d3f826062_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24332264","allele":{"id":"https://genegraph.clinicalgenome.org/r/955b6e6f-849a-4852-b00f-047ea852cf38","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006785.4(MALT1):c.1739G>C (p.Trp580Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA151385"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/1d2e674d-f725-4bb8-a22b-b62df9c74b67","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24332264","rdfs:label":"IV.1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":15,"allele":{"id":"https://genegraph.clinicalgenome.org/r/955b6e6f-849a-4852-b00f-047ea852cf38"},"detectionMethod":"Exome followed by Sanger","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001581","obo:HP_0000704","obo:HP_0002110","obo:HP_0004325","obo:HP_0001217","obo:HP_0006532","obo:HP_0004322","obo:HP_0004386","obo:HP_0002757"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/354dd027-34d9-444d-99d5-830d3f826062_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":5507,"specifiedBy":"GeneValidityCriteria9","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/rwXcF8G1uHg","type":"GeneValidityProposition","disease":"obo:MONDO_0014197","gene":"hgnc:6819","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_537efc87-5f45-489b-9aa0-6bd3e029754e-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}